No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Clinical benefit seen with ibrutinib for relapsed/refractory multiple mantle cell lymphoma in a real-world population

byKathleen Lau

March 11, 2021

in StudyGraphics

#VisualAbstract: Circulating tumor DNA levels may predict treatment response in patients with advanced melanoma

RelatedReports

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Chronic Disease

The incidence of early-onset metastatic adenocarcinoma may be higher among patients with multiple metastatic sites and peritoneal involvement

April 30, 2026

Thoracic radiotherapy improves survival in small-cell lung cancer patients

Chronic Disease

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

April 15, 2026

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization

Cardiology

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

April 9, 2026

Radiation plus hormone therapy may improve prostate cancer survival

Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 9, 2026

RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time

Screening plus Eave Tubes provides a cost-effective strategy to alleviate burden of malaria in Côte d’Ivoire

Epidemiologic features of the 2018-2019 measles outbreak in New York City

Study details societal costs of a measles outbreak

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Resuming oral anticoagulant (OAC) therapy after an OAC-related bleed associated with higher rates of bleeding

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports